ABIGAIL CUMMINGS: Open Payments
NPI 1184226201 · LEWISTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,579 in 238 payments from 15 companies in 2025. Trend: 2023 $2,998 · 2024 $3,198 · 2025 $3,579
Food & beverage: $3,579
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 33 | $677 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 56 | $504 |
| Neurocrine BioSciences, Inc. | 22 | $366 |
| Collegium Pharmaceutical, Inc. | 24 | $337 |
| ABBVIE INC. | 25 | $300 |
| Alkermes, Inc. | 14 | $284 |
| E.R. Squibb & Sons, L.L.C. | 14 | $210 |
| Lundbeck LLC | 13 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $189 |
| Janssen Pharmaceuticals, Inc | 10 | $180 |
Products named: REXULTI, CAPLYTA, INGREZZA, Jornay PM, VRAYLAR, ABILIFY MAINTENA, COBENFY, TRINTELLIX.
Industry payments across PA — which companies pay providers there.
